Composition for preventing or treating nicotine addiction, which contains liriope latifolia extract as active ingredient

• Main Authors: LEE YOUNG-SEOB, RYU IN-SOO, BAN JAE-SUK, LEE DAE-YOUNG, KIM TAE-WAN, SEO JEONG-UK, KIM GEUM-SOOG, YOON DA-HYE, LIM RI-NA, KA MIN-HAN
• Format: Patent
• Language: Chinese; English
• Published: 08.12.2020
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The invention relates to an application of a liriope latifolia extract in preparation of a medicine for preventing or treating nicotine addiction. The present invention is accomplished by confirming that a liriope latifolia extract can be effectively used as an active ingredient for preventing and treating nicotine addiction, and the liriope latifolia extract regulates changes in the expression level of tyrosine hydroxylase (TH) protein and dopamine transporter (DAT) protein caused by nicotine, and the increase of spontaneous activity of nicotine addicted rats is inhibited. 本发明涉及阔叶山麦冬提取物在制备用于预防或治疗尼古丁成瘾的药物中的用途。本发明通过确认阔叶山麦冬提取物能够有效地用作预防和治疗尼古丁成瘾的有效成分而完成，由于该阔叶山麦冬提取物调节尼古丁引起的酪氨酸羟化酶(TH)蛋白和多巴胺转运体(DAT)蛋白的表达水平的变化，并抑制了尼古丁成瘾大鼠的自发活动的增加。